Isis Pharmaceuticals (ISIS) 42.28 $ISIS
3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
Uptrend Call Working As Isis Pharmaceuticals Stock Rises 25.7% (ISIS)
Comtex SmarTrend(R) - Thu Sep 18, 9:15AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 1 month, Isis Pharmaceuticals has returned 25.74% as of today's recent price of $41.65.
Isis Pharmaceuticals earns USD4m for Plazomicin's clinical development for treating serious bacterial infections
M2 - Thu Sep 18, 5:56AM CDT
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Wednesday that it has earned a USD4m milestone payment for its Plazomicin drug from Achaogen (NasdaqGM:AKAO).
Jim Cramer's Top Stock Picks: ISIS DDD CY
at The Street - Thu Sep 18, 5:00AM CDT
Cramer is a big fan of Cypress Semiconductor and wants you to buy, buy, buy DuPont.
Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve
at The Street - Wed Sep 17, 7:08PM CDT
Now that the Fed has done the right thing on monetary policy, investors should stop worrying and start thinking about how to make more money, Cramer says.
Biotech Stocks in Motion - XOMA, Nanosphere, Isis Pharma, Halozyme Therapeutics, and Synta Pharma
PR Newswire - Wed Sep 17, 7:45AM CDT
The US markets on Tuesday, September 16, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,131.97, up 0.59% and the NASDAQ Composite closed at 4,552.76, up 0.75%. The S&P 500 finished the session 0.75% higher at 1,998.98. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 744.20, up 1.34%, with the index gaining 7.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: XOMA Corporation (NASDAQ: XOMA), Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at:
Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin
PR Newswire - Wed Sep 17, 6:26AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that it has earned a $4 million milestone payment from Achaogen, Inc. (NASDAQ: AKAO) associated with the initiation of a Phase 3 study of plazomicin in patients with serious multi-drug resistant (MDR), gram-negative bacterial infections. The Phase 3 study is designed as a superiority study to evaluate the efficacy and safety of plazomicin compared to colistin in patients with bloodstream infections and nosocomial pneumonia caused by carbapenem-resistant Enterobacteriaceae (CRE). Achaogen announced last year that it has reached a special protocol assessment, or SPA, with the U.S. Food and Drug Administration for this Phase 3 study.
Why Anxious Investors' Pressure Could Push Small Cap Stocks Lower
at The Street - Tue Sep 16, 1:09PM CDT
Small-cap stocks are experiencing selling pressure this week as volatility rises as world event prey on investor uncertainty.
Critical Alerts For Intel, Zynga, Isis Pharmaceuticals, Arrowhead Research and MannKind Released By InvestorsObserver
PR Newswire - Tue Sep 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INTC, ZNGA, ISIS, ARWR and MNKD.
Why ISIS Pharmaceuticals Inc. Stock Is Flat in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 12, 8:05AM CDT
ISIS Pharmaceuticals; Source: Google Maps It's been a tough year for ISIS Pharmaceuticals investors. After a remarkable 281% return in 2013, shares have gone absolutely nowhere in 2014. That flat-line return is even more disappointing...
Jim Cramer's Top Stock Picks: TWTR TASR ACAD ISIS RH
at The Street - Fri Sep 12, 5:00AM CDT
Arcadia Pharmaceuticals and Isis Pharmaceuticals are the next big biotech takeover targets, Cramer says.
Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Review 2014 - 17 Companies & 27 Drug Profiles
M2 - Fri Sep 12, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r5vn8b/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Genzyme Corporation - F. Hoffmann-La Roche Ltd. - Isis Pharmaceuticals, Inc. - Pfizer Inc. - Zambon Company S.p.A. - Paratek Pharmaceuticals, Inc. - Cytokinetics, Inc. - Neurotune AG - Trophos SA - Nexgenix Pharmaceuticals, LLC - Genethon - Vybion, Inc. - OrphageniX, Inc. - Retrophin, LLC - Neurodyn Inc. - GMP-Orphan SAS - Cellular Biomedicine Group, Inc. Drug Profiles - olesoxime - ISIS-SMNRx - PF-06687859 - RG-7800 - Gene Therapy to Activate SMN for Spinal Muscular Atrophy - AAV9-SMN Gene Therapy - tirasemtiv - PTK-SMA-2 - NXD-30001 - DNA Oligonucleotides for Spinal Muscular Atrophy - RE-003 - Gene Therapy for Spinal Muscular Atrophy - ND-602 - Antisense Oligonucleotide for Spinal Muscular Atrophy and Myotonic Dystrophy - Motor Neuron Precursor Cells - Small Molecule to Activate SMN Protein for Spinal Muscular Atrophy - Agrin Biologic For SMA - sodium phenylbutyrate - Small Molecules for CNS Disorders - PMO-25 - Synthetic Peptides for Central Nervous System Disorders - BBrm-01 - Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - INT-41 - Antisense Oligonucleotides for Spinal Muscular Atrophy - ZP-037 For more information visit http://www.researchandmarkets.com/research/r5...l_muscular
Jim Cramer's 'Mad Money' Recap: Enjoy This Bull Market While It Lasts
at The Street - Thu Sep 11, 6:47PM CDT
As long as it's here, good things are happening every day, Cramer says.
Isis Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.84%
Comtex SmarTrend(R) - Thu Sep 11, 4:34PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $38.84 to a high of $41.07. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $39.90 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
'Mad Money' Lightning Round: Buy, Buy, Buy Flextronics
at The Street - Thu Sep 11, 5:00AM CDT
Cramer likes Xerox, Sysco and Seattle Genetics.
Jim Cramer's 'Mad Money' Recap: This Is Why Apple Rules
at The Street - Wed Sep 10, 7:10PM CDT
Apple is one of a number of innovators whose shares have risen and rewarded shareholders, Cramer says.
Isis Pharmaceuticals Shares Up 15.6% Since SmarTrend's Buy Recommendation (ISIS)
Comtex SmarTrend(R) - Wed Sep 10, 11:14AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 1 month, Isis Pharmaceuticals has returned 15.59% as of today's recent price of $38.29.
National Association of Professional Women Announces Lou Ellen Phillips-Smith, Ph.D., Medical Writing Consultant, a 2014 Professional Woman of the Year
PRWeb - Mon Sep 08, 11:06PM CDT
NAPW honors Lou Ellen Phillips-Smith, Ph.D., Medical Writing Consultant, as a 2014 Professional Woman of the Year. Ms. Phillips-Smith is recognized with this prestigious distinction for leadership in clinical science. As the largest networking organization of professional women in the country, spanning virtually every industry and profession, the National Association of Professional Women is a vibrant networking community with over 600,000 members and nearly 300 Local Chapters.
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
Isis Pharmaceuticals Falls 2.12% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Sep 05, 4:48PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $37.06 to a high of $38.98. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $38.95 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
Uptrend Call Working As Isis Pharmaceuticals Stock Rises 25.7% (ISIS)
Comtex SmarTrend(R) - Thu Sep 18, 9:15AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 1 month, Isis Pharmaceuticals has returned 25.74% as of today's recent price of $41.65.
Isis Pharmaceuticals earns USD4m for Plazomicin's clinical development for treating serious bacterial infections
M2 - Thu Sep 18, 5:56AM CDT
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Wednesday that it has earned a USD4m milestone payment for its Plazomicin drug from Achaogen (NasdaqGM:AKAO).
Jim Cramer's Top Stock Picks: ISIS DDD CY
at The Street - Thu Sep 18, 5:00AM CDT
Cramer is a big fan of Cypress Semiconductor and wants you to buy, buy, buy DuPont.
Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve
at The Street - Wed Sep 17, 7:08PM CDT
Now that the Fed has done the right thing on monetary policy, investors should stop worrying and start thinking about how to make more money, Cramer says.
Biotech Stocks in Motion - XOMA, Nanosphere, Isis Pharma, Halozyme Therapeutics, and Synta Pharma
PR Newswire - Wed Sep 17, 7:45AM CDT
The US markets on Tuesday, September 16, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,131.97, up 0.59% and the NASDAQ Composite closed at 4,552.76, up 0.75%. The S&P 500 finished the session 0.75% higher at 1,998.98. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 744.20, up 1.34%, with the index gaining 7.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: XOMA Corporation (NASDAQ: XOMA), Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at:
Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin
PR Newswire - Wed Sep 17, 6:26AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that it has earned a $4 million milestone payment from Achaogen, Inc. (NASDAQ: AKAO) associated with the initiation of a Phase 3 study of plazomicin in patients with serious multi-drug resistant (MDR), gram-negative bacterial infections. The Phase 3 study is designed as a superiority study to evaluate the efficacy and safety of plazomicin compared to colistin in patients with bloodstream infections and nosocomial pneumonia caused by carbapenem-resistant Enterobacteriaceae (CRE). Achaogen announced last year that it has reached a special protocol assessment, or SPA, with the U.S. Food and Drug Administration for this Phase 3 study.
Why Anxious Investors' Pressure Could Push Small Cap Stocks Lower
at The Street - Tue Sep 16, 1:09PM CDT
Small-cap stocks are experiencing selling pressure this week as volatility rises as world event prey on investor uncertainty.
Critical Alerts For Intel, Zynga, Isis Pharmaceuticals, Arrowhead Research and MannKind Released By InvestorsObserver
PR Newswire - Tue Sep 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INTC, ZNGA, ISIS, ARWR and MNKD.
Why ISIS Pharmaceuticals Inc. Stock Is Flat in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 12, 8:05AM CDT
ISIS Pharmaceuticals; Source: Google Maps It's been a tough year for ISIS Pharmaceuticals investors. After a remarkable 281% return in 2013, shares have gone absolutely nowhere in 2014. That flat-line return is even more disappointing...
Jim Cramer's Top Stock Picks: TWTR TASR ACAD ISIS RH
at The Street - Fri Sep 12, 5:00AM CDT
Arcadia Pharmaceuticals and Isis Pharmaceuticals are the next big biotech takeover targets, Cramer says.
Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Review 2014 - 17 Companies & 27 Drug Profiles
M2 - Fri Sep 12, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r5vn8b/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Genzyme Corporation - F. Hoffmann-La Roche Ltd. - Isis Pharmaceuticals, Inc. - Pfizer Inc. - Zambon Company S.p.A. - Paratek Pharmaceuticals, Inc. - Cytokinetics, Inc. - Neurotune AG - Trophos SA - Nexgenix Pharmaceuticals, LLC - Genethon - Vybion, Inc. - OrphageniX, Inc. - Retrophin, LLC - Neurodyn Inc. - GMP-Orphan SAS - Cellular Biomedicine Group, Inc. Drug Profiles - olesoxime - ISIS-SMNRx - PF-06687859 - RG-7800 - Gene Therapy to Activate SMN for Spinal Muscular Atrophy - AAV9-SMN Gene Therapy - tirasemtiv - PTK-SMA-2 - NXD-30001 - DNA Oligonucleotides for Spinal Muscular Atrophy - RE-003 - Gene Therapy for Spinal Muscular Atrophy - ND-602 - Antisense Oligonucleotide for Spinal Muscular Atrophy and Myotonic Dystrophy - Motor Neuron Precursor Cells - Small Molecule to Activate SMN Protein for Spinal Muscular Atrophy - Agrin Biologic For SMA - sodium phenylbutyrate - Small Molecules for CNS Disorders - PMO-25 - Synthetic Peptides for Central Nervous System Disorders - BBrm-01 - Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - INT-41 - Antisense Oligonucleotides for Spinal Muscular Atrophy - ZP-037 For more information visit http://www.researchandmarkets.com/research/r5...l_muscular
Jim Cramer's 'Mad Money' Recap: Enjoy This Bull Market While It Lasts
at The Street - Thu Sep 11, 6:47PM CDT
As long as it's here, good things are happening every day, Cramer says.
Isis Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.84%
Comtex SmarTrend(R) - Thu Sep 11, 4:34PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $38.84 to a high of $41.07. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $39.90 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
'Mad Money' Lightning Round: Buy, Buy, Buy Flextronics
at The Street - Thu Sep 11, 5:00AM CDT
Cramer likes Xerox, Sysco and Seattle Genetics.
Jim Cramer's 'Mad Money' Recap: This Is Why Apple Rules
at The Street - Wed Sep 10, 7:10PM CDT
Apple is one of a number of innovators whose shares have risen and rewarded shareholders, Cramer says.
Isis Pharmaceuticals Shares Up 15.6% Since SmarTrend's Buy Recommendation (ISIS)
Comtex SmarTrend(R) - Wed Sep 10, 11:14AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 1 month, Isis Pharmaceuticals has returned 15.59% as of today's recent price of $38.29.
National Association of Professional Women Announces Lou Ellen Phillips-Smith, Ph.D., Medical Writing Consultant, a 2014 Professional Woman of the Year
PRWeb - Mon Sep 08, 11:06PM CDT
NAPW honors Lou Ellen Phillips-Smith, Ph.D., Medical Writing Consultant, as a 2014 Professional Woman of the Year. Ms. Phillips-Smith is recognized with this prestigious distinction for leadership in clinical science. As the largest networking organization of professional women in the country, spanning virtually every industry and profession, the National Association of Professional Women is a vibrant networking community with over 600,000 members and nearly 300 Local Chapters.
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
Isis Pharmaceuticals Falls 2.12% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Sep 05, 4:48PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $37.06 to a high of $38.98. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $38.95 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
